About the GHIT Fund


Press Room

Correction Notice

2013.12.04

Please note the correction below to our press release in Japanese which was distributed on Novermber 8, 2013 titled "Japanese Fund Moves Quickly to Invest in Promising Technology Against Malaria, Tuberculosis And Chagas Disease", the name of drug candidate of Medicines for Malaria Venture and Takeda Pharmacuetical Company Limited was mistakenly described as DSM256. The corrected name is DSM265.

 

We deeply apologize for the error in the press release. 

 

GHIT Fund

Ark Hills Sengokuyama Mori Tower 25F, 1-9-10 Roppongi, Minato-ku, Tokyo 106-0032
TEL:+81-36441-2032 FAX:+81-36441-2031 E-mail:info@ghitfund.org